106 related articles for article (PubMed ID: 36543899)
1. Authors' reply to Dr. Paolo Duarte: Combined [68Ga]Ga-PSMA-11 and low-dose [18F]FDG PET/CT using a long-axial field of view scanner for patients referred for [177Lu]-PSMA-radioligand therapy.
Alberts I; Schepers R; Zeimpekis K; Sari H; Rominger A; Afshar-Oromieh A
Eur J Nucl Med Mol Imaging; 2023 Feb; 50(3):644-647. PubMed ID: 36543899
[No Abstract] [Full Text] [Related]
2. Combined [68 Ga]Ga-PSMA-11 and low-dose 2-[18F]FDG PET/CT using a long-axial field of view scanner for patients referred for [177Lu]-PSMA-radioligand therapy.
Alberts I; Schepers R; Zeimpekis K; Sari H; Rominger A; Afshar-Oromieh A
Eur J Nucl Med Mol Imaging; 2023 Feb; 50(3):951-956. PubMed ID: 36136102
[TBL] [Abstract][Full Text] [Related]
3. Letter to the editor: Combined [
Duarte PS
Eur J Nucl Med Mol Imaging; 2023 Feb; 50(3):642-643. PubMed ID: 36258051
[No Abstract] [Full Text] [Related]
4. Fibroblast Activation Protein-Targeted PET Imaging of Metastatic Castration-Resistant Prostate Cancer Compared With 68Ga-PSMA and 18F-FDG PET/CT.
Isik EG; Has-Simsek D; Sanli O; Sanli Y; Kuyumcu S
Clin Nucl Med; 2022 Jan; 47(1):e54-e55. PubMed ID: 34392294
[TBL] [Abstract][Full Text] [Related]
5. The Triple-Tracer strategy against Metastatic PrOstate cancer (3TMPO) study protocol.
Pouliot F; Beauregard JM; Saad F; Trudel D; Richard PO; Turcotte É; Rousseau É; Probst S; Kassouf W; Anidjar M; Camirand Lemyre F; Bouvet GF; Neveu B; Tétu A; Guérin B
BJU Int; 2022 Sep; 130(3):314-322. PubMed ID: 34674367
[TBL] [Abstract][Full Text] [Related]
6. Differentiating benign and malignant pancreatic masses: Ga-68 PSMA PET/CT as a new diagnostic avenue.
Krishnaraju VS; Kumar R; Mittal BR; Sharma V; Singh H; Nada R; Bal A; Rohilla M; Singh H; Rana SS
Eur Radiol; 2021 Apr; 31(4):2199-2208. PubMed ID: 33001304
[TBL] [Abstract][Full Text] [Related]
7. Positron Emission Tomography/Computed Tomography in Thyroid Cancer.
Bal C; Chakraborty D; Khan D
PET Clin; 2022 Apr; 17(2):265-283. PubMed ID: 35256297
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic value of
Chen R; Wang Y; Shi Y; Zhu Y; Xu L; Huang G; Liu J
Eur J Nucl Med Mol Imaging; 2021 Aug; 48(9):2970-2977. PubMed ID: 33528607
[TBL] [Abstract][Full Text] [Related]
9. 68Ga-PSMA-HBED-CC PET/CT and 18F-FDG PET/CT in Ewing Sarcoma.
Parihar AS; Sood A; Mittal BR; Kumar R; Singh H; Dhatt SS
Clin Nucl Med; 2020 Jan; 45(1):e57-e58. PubMed ID: 31524682
[TBL] [Abstract][Full Text] [Related]
10. Topical Sensor for the Assessment of Injection Quality for 18F-FDG, 68Ga-PSMA and 68Ga-DOTATATE Positron Emission Tomography.
Sanchez S; Currie GM
J Med Imaging Radiat Sci; 2020 Jun; 51(2):247-255. PubMed ID: 32089515
[TBL] [Abstract][Full Text] [Related]
11. The roles of 68 Ga-PSMA PET/CT and 18 F-FDG PET/CT imaging in patients with triple-negative breast cancer and the association of tissue PSMA and claudin 1, 4, and 7 levels with PET findings.
Arslan E; Ergül N; Beyhan E; Erol Fenercioglu Ö; Sahin R; Cin M; Battal Havare S; Can Trabulus FD; Mermut Ö; Akbas S; Fikret Çermik T
Nucl Med Commun; 2023 Apr; 44(4):284-290. PubMed ID: 36756767
[TBL] [Abstract][Full Text] [Related]
12. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic Value of 68Ga PSMA-11 PET/CT Imaging of Brain Tumors-Preliminary Analysis.
Sasikumar A; Joy A; Pillai MR; Nanabala R; Anees K M; Jayaprakash PG; Madhavan J; Nair S
Clin Nucl Med; 2017 Jan; 42(1):e41-e48. PubMed ID: 27846000
[TBL] [Abstract][Full Text] [Related]
14.
Parihar AS; Mittal BR; Kumar R; Shukla J; Bhattacharya A
Thyroid; 2020 Apr; 30(4):557-567. PubMed ID: 31870227
[No Abstract] [Full Text] [Related]
15. PET/CT using
Liu D; Cheng G; Ma X; Wang S; Zhao X; Zhang W; Yang W; Wang J
J Neuroimaging; 2021 Jul; 31(4):733-742. PubMed ID: 34021667
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic performances of 68Ga-DOTATOC versus 18Fluorodeoxyglucose positron emission tomography in pulmonary carcinoid tumours and interrelationship with histological features.
Lococo F; Rapicetta C; Mengoli MC; Filice A; Paci M; Di Stefano T; Coruzzi C; Versari A
Interact Cardiovasc Thorac Surg; 2019 Jun; 28(6):957-960. PubMed ID: 30753507
[TBL] [Abstract][Full Text] [Related]
17. Impact of the new ultra-high sensitivity mode in a long axial field-of-view PET/CT.
Mingels C; Weidner S; Sari H; Buesser D; Zeimpekis K; Shi K; Alberts I; Rominger A
Ann Nucl Med; 2023 May; 37(5):310-315. PubMed ID: 36913094
[TBL] [Abstract][Full Text] [Related]
18. How accurate is
Erdem S; Simsek DH; Degirmenci E; Aydin R; Bagbudar S; Ozluk Y; Sanli Y; Sanli O; Ozcan F
Urol Oncol; 2022 Jan; 40(1):6.e1-6.e9. PubMed ID: 34400066
[TBL] [Abstract][Full Text] [Related]
19. Histological Validation of FDG and PSMA-Targeted PET/CT Imaging in a Rare Tracheal Adenoid Cystic Carcinoma.
Sandach P; Seifert R; Slama A; Theegarten D; Hautzel H
Clin Nucl Med; 2023 Jan; 48(1):e16-e18. PubMed ID: 36469074
[TBL] [Abstract][Full Text] [Related]
20. 68 Ga-FAPI PET/CT Detected Non-PSMA/FDG-Avid Primary Tumor in De Novo Metastatic Prostate Cancer.
Pang Y; Meng T; Xu W; Shang Q; Chen H
Clin Nucl Med; 2022 Dec; 47(12):1108-1111. PubMed ID: 35961368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
